Canopy Health Innovations, the recently formed research incubator partly owned by Canopy Growth Corporation, has entered into a 3-year consulting agreement with EPIC Consulting Inc., the Quebec-based consulting firm of Dr. Mark Ware.
Canopy Health Innovations was established to research and develop clinically ready cannabis drug formulations and delivery systems for both human and/or animal patients targeting unmet medical needs in traditional pharmaceutical markets that could be disrupted by cannabis-based options. Under a framework agreement with CHI, Canopy Growth retains the right of first refusal to commercialize all resulting intellectual property developed by CHI globally.
"Canadian policy and regulations around cannabis are very progressive when compared to other jurisdictions around the world," said Marc Wayne, President and Director of CHI. "We have a unique opportunity here in Canada to study cannabis and develop products that will change the world. Bringing Dr. Ware in at this exciting moment to consult on our clinical research strategy is an important step towards our vision of bringing validated cannabis medicines to market as quickly as possible."
Dr. Mark Ware has been conducting medical cannabis research in Canada for more than 19 years and brings considerable expertise in the design of high quality clinical studies to evaluate the safety and efficacy of cannabinoids. "I am pleased to support the work that CHI is doing to develop cannabinoid medicines, and to help generate important data for patients and health care providers regarding the safety and efficacy of cannabis-based therapies" stated Dr. Ware. "EPIC was established to guide organizations in identifying and developing credible and evidence-based approaches to address the considerable gaps that currently exist in our understanding of the safe use of cannabis".
Dr. Ware's guidance will be instrumental for CHI research planning. With access to cannabis products from Canada's largest and most diverse production platform, Tweed's Dealer's License under Section 56 of the Controlled Drugs and Substances Act, and research data from studies operated by Canopy Growth subsidiaries, CHI's access to research tools is significant.
For more information:
Canopy Growth
1 Hershey Dr.
Smiths Falls, Ontario
K7A 0A8
1 855 558 9333 x 122
invest@canopygrowth.com
www.canopygrowth.com
Announcements
Vacancies
Canada: Canopy boosts MMJ research
Publication date:
Receive the daily newsletter in your email for free | Click here
Other news in this sector:
- 2023-12-01 Mendo partners with JC Green to further strengthen medical cannabis platform
- 2023-12-01 Kurt Dramm inducted into The Green Industry Hall of Fame
- 2023-11-30 BioTherm unveils new cultivation solutions at MJBizCon 2023
- 2023-11-30 US (MN): Cohasset company seeks license to grow
- 2023-11-30 Curio Wellness achieves Good Agriculture Collection Practices (GACP)
- 2023-11-30 Earl Reinink retires from Westbrook Systems
- 2023-11-29 Periodic table of cannabis molecules launched to mutually educate consumers and industry leaders
- 2023-11-29 FundCanna hires Terme Hayempour as director of partnerships
- 2023-11-29 "Our software has processed 80,000 harvests last year alone"
- 2023-11-29 SteraMist welcomes Sterile Grow as U.S. distributor for food safety and cannabis
- 2023-11-28 Bluelab unveils controller upgrade
- 2023-11-27 Partnership combines odor elimination with air sanitization
- 2023-11-24 Helius Therapeutics CEO wins Inspiring Women Leaders Award
- 2023-11-24 US: DEA-approved cannabis company to raise capital
- 2023-11-23 UK-based medical cannabis producer announces supplier agreement
- 2023-11-23 Las- & Montagebedrijf FBO and the Voorwinden Group continue together
